Medmira (MIR) AI Stock Analysis

• Market Cap: C$55.81M
• Dividend Yield: N/A
• Average Volume (3M): 47.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: -33.66%
• EPS Growth: -48.89%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 697,666,140
• 10 Day Avg. Volume: 70,203
• 30 Day Avg. Volume: 47,146
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Medmira's stock score is primarily impacted by its poor financial performance, characterized by negative profitability and high financial leverage. The technical analysis suggests a bearish trend, further weighing on the stock's outlook. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, indicating a lack of investor appeal. Significant improvements in financial health and operational efficiency are necessary to enhance the stock's attractiveness.

Medmira Business Overview & Revenue Model

Company Description

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

How the Company Makes Money

Medmira makes money through the sale of its rapid diagnostic testing products to healthcare providers, clinics, and laboratories. The company's revenue model primarily revolves around direct sales and distribution agreements with partners in different regions. Medmira also engages in licensing agreements, where it provides its proprietary technology to third-party manufacturers or distributors. Significant partnerships with healthcare organizations and government entities further contribute to its earnings, as these collaborations often lead to bulk purchase agreements and expanded market reach. Additionally, Medmira may receive funding from research grants and initiatives aimed at enhancing public health diagnostic capabilities.

Medmira Financial Statement Overview

Summary

Medmira is facing significant financial challenges across all major statements. The company is struggling with profitability, financial stability, and cash generation. High leverage and negative equity raise concerns about solvency, while negative margins and cash flows highlight operational inefficiencies. Significant improvements are needed to enhance the financial health and sustainability of the company.

Income Statement

Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.

Balance Sheet

The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	254.30K	412.57K	432.53K	952.13K	2.14M	919.07K
Gross Profit	178.85K	226.49K	-434.91K	304.03K	1.72M	572.28K
EBITDA	-3.24M	-2.13M	-1.58M	-1.07M	185.30K	-1.13M
Net Income	-4.66M	-3.33M	-2.68M	-1.83M	-675.80K	-2.05M
Balance Sheet
Total Assets	3.78M	6.07M	3.65M	3.83M	3.89M	3.40M
Cash, Cash Equivalents and Short-Term Investments	18.28K	2.10M	13.18K	33.46K	-2.30M	401.86K
Total Debt	10.16M	9.56M	9.27M	8.30M	11.54M	11.91M
Total Liabilities	25.30M	24.11M	18.68M	16.19M	19.61M	18.96M
Stockholders Equity	-21.52M	-18.04M	-15.03M	-12.36M	-15.72M	-15.56M
Cash Flow
Free Cash Flow	-4.14M	-3.68M	-1.27M	-1.95M	-541.19K	-417.78K
Operating Cash Flow	-3.39M	-2.94M	-1.27M	-1.88M	-504.64K	-315.90K
Investing Cash Flow	-746.19K	-742.53K	-1.27K	-69.72K	-36.55K	-101.88K
Financing Cash Flow	1.25M	5.77M	1.25M	1.99M	139.32K	730.74K

Medmira Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.06 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	74 Outperform	C$62.51M	27.01	9.01%	―	13.00%	―
MBX	57 Neutral	C$32.91M	24.14	-1.13%	―	-9.54%	-105.12%
Sector *	51 Neutral	$7.95B	-0.40	-41.67%	2.21%	22.29%	-1.85%
MIR	41 Neutral	C$55.81M	―		―	-33.66%	-48.89%
ONCY	―	$109.35M	―	-244.84%	―	―	―
SVA	33 Underperform	C$64.05M	―	248.46%	―	―	49.34%
HBP	33 Underperform	C$107.53M	―	685.26%	―	―	-31.12%

Medmira Corporate Events

MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada

MedMira has launched a clinical trial for its Multiplo® TP/HIV self-test in Canada, marking a significant step in addressing the rising cases of HIV and syphilis in the country. The trial, supported by Health Canada and funded by the Canadian Institutes of Health Research, aims to bring the self-test to communities in need, bypassing traditional regulatory steps. This initiative is expected to empower individuals with privacy and control over their health, potentially reducing the spread of these infections by providing immediate results and facilitating access to care.

MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing

MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.